EMA Archives

La EMA autoriza a ORYZON un Fase Ib de iadademstat en anemia falciforme

Primer ensayo clínico de iadademstat en una indicación hematológica no maligna Oryzon Genomics S.A., compañía biofarmacéutica de fase clínica y

El nuevo régimen de dosificación recomendado redujo significativamente las tasas de ARIA en comparación con la pauta posológica original, reforzando

El pasado día 28 de junio la Agencia Europea del Medicamento (EMA) emitió un comunicado por el que recomendaba a

Cookie	Duración	Descripción
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.